找到相關結果： 956

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

Abstract (download poster for full details): Authors: Jian-Ming Xu, Lin Shen, Yan Wang, Yu-ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Hua Ye, Su Weiguo Background: Sulfatinib is a highly selective oral small molecule inhi

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-11-06

和黃醫藥啟動索凡替尼在美國的臨床試驗

1 個附件

2015年11月6日：和黃醫藥今日宣布啟動索凡替尼（HMPL-012）在美國的I期臨床試驗。該藥的美國新藥臨床研究申請於今年遞交並通過，2015年11月4日首位受試者接受給藥治療。此外，和黃醫藥將�

查看公告 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-10-30

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa

公告及新聞稿, 監管通知 | 2015-10-30

Total Voting Rights

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-10-30

和黃醫藥宣布新型Syk 抑製劑HMPL-523治療免疫疾病的I期臨床試驗取得成功

1 個附件

2015 年10 月30 日: 和黃醫藥（上海）有限公司（簡稱“ 和黃醫藥” ）今日宣布成功完成HMPL ‑ 523 的I 期臨床試驗。HMPL-523 是針對B 細胞受體信號通路中的酪氨酸激酶Syk 的新型高選擇�

查看公告 (PDF)

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-10-23

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt

公告及新聞稿, 監管通知 | 2015-10-20

Director's Share Dealing

London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi

公告及新聞稿, 監管通知 | 2015-10-19

Awards under Long Term Incentive Plan

London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP

公告及新聞稿, 新聞稿, 集團 | 2015-10-16

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti

公告及新聞稿, 集團 | 2015-10-16

Shareholders' Circular and Notice of Extraordinary General Meeting

London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U

公告及新聞稿, 集團 | 2015-10-16

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-10-13

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma

Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha

公告及新聞稿, 監管通知 | 2015-10-12

Holding(s) in Company

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or t

公告及新聞稿, 集團 | 2015-10-08

Winner of International Company of the Year 2015, AIM

At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners

演示文稿, 科學出版物 | 2015-09-27

ESMO 2015: Phase II trial of fruquintinib in metastatic colorectal cancer

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-09-14

和黃醫藥將在2015歐洲癌症大會公佈呋喹替尼治療結直腸癌的II期臨床研究結果

1 個附件

2015 年9 月14 日：和黃醫藥今日宣布將在2015 年9 月25 日至29 日於奧地利維也納舉行的歐洲癌症大會上公佈呋喹替尼治療轉移性結直腸癌臨床II 期概念驗證性試驗的詳細研究結果。呋喹替尼是

查看公告 (PDF)

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-09-02

呋喹替尼第二個概念驗證性臨床研究達到主要終點

1 個附件

2015 年9 月2 日: 和黃醫藥今日宣布呋喹替尼以晚期非鱗狀非小細胞肺癌（NSCLC）為適應症的第二個概念驗證性（POC）臨床研究成功達到主要終點。研究結果顯示該試驗成功地達到了無進展�

查看公告 (PDF)

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-08-19

和黃醫藥與楊森製藥終止HMPL-507項目相關的合作協議

1 個附件

2015 年8 月19 日星期三：和黃醫藥今日宣布收到楊森製藥( Janssen Pharmaceutical, Inc.) 關於終止HMPL-507 項目的合作研發協議的決定。和黃醫藥與楊森製藥於2008 年開始戰略合作，並於2010 年

查看公告 (PDF)

公告及新聞稿, 集團 | 2015-07-28

Interim Results for the Six Months Ended 30 June 2015

For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-07-23

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med

London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui

公告及新聞稿, 其他業務 | 2015-07-17

20-year invention patent granted on Chi-Med's best selling prescription drug

London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven

公告及新聞稿, 監管通知 | 2015-07-06

Notice of Announcement of 2015 Interim Results

London: Monday, 6 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) will be announcing its interim results for the six months ended 30 June 2015 on Tuesday, 28 July 2015. An analyst presentation will be held at 9:00 am on the same d

公告及新聞稿, 監管通知 | 2015-06-29

Blocklisting Six Monthly Return

London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-06-01

和黃醫藥在2015年度ASCO大會上公佈沃利替尼 (AZD6094) Ib 期肺癌臨床數據

2015 年6 月1 日: 和黃醫藥今日宣布，其合作夥伴阿斯利康公佈了由和黃醫藥自主研發的c-Met 抑製劑沃利替尼（AZD6094）與阿斯利康的候選藥物AZD9291 聯合用藥治療非小細胞肺癌的Ib 期臨床�

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-05-13

呋喹替尼首個概念驗證性臨床研究成功，和黃醫藥獲得1800萬美元里程碑付款

1 個附件

星期二，2015 年5 月12 日：和黃中國醫藥科技有限公司今日宣布呋喹替尼以轉移性結直腸癌為適應症的首個概念驗證性（POC）臨床研究達到預期終點，成功觸發第一個里程碑，和黃醫藥將於201

查看公告 (PDF)

演示文稿, 科學出版物 | 2015-05-01

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Please see http://meetinglibrary.asco.org/content/109556 The associated abstract is available at http://meetinglibrary.asco.org/content/148945-156. Meeting: 2015 ASCO Annual Meeting Session: Developmental Therapeutics – Clinical Pharmacol

公告及新聞稿, 監管通知 | 2015-04-30

Total Voting Rights

London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to

公告及新聞稿, 監管通知 | 2015-04-24

Results of Annual General Meeting

London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 24 April 2015 were duly passed. Please download the PDF.

公告及新聞稿, 監管通知 | 2015-04-22

Director's Shareholding

London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 pe

公告及新聞稿, 監管通知 | 2015-04-16

Director's Shareholding

London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15

公告及新聞稿, 監管通知 | 2015-04-13

Director's Shareholding

London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP14.215 per share on 10 A

公告及新聞稿, 監管通知 | 2015-04-08

Directors' Shareholding

London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase

公告及新聞稿, 監管通知 | 2015-04-01

Exercise of Options

London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercis

公告及新聞稿, 監管通知 | 2015-04-01

Directors' Shareholding

London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase Numbe

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-03-30

呋喹替尼的首個概念驗證性（POC）臨床研究達到主要療效終點

1 個附件

2015 年3 月30 日：和黃醫藥今日宣布呋喹替尼以轉移性結直腸癌為適應症的首個概念驗證性（POC）臨床研究成功達到主要試驗終點。研究結果顯示該試驗成功地達到了無進展生存期的主要療

查看公告 (PDF)

公告及新聞稿, 監管通知 | 2015-03-23

2014 Annual Report and Notice of Annual General Meeting

London: Monday, 23 March 2015: Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.

公告及新聞稿, 監管通知 | 2015-03-18

TR-1: Notification of major interest in shares

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-03-06

呋喹替尼治療非小細胞肺癌的II期臨床試驗完成受試者入組；治療非小細胞肺癌、結直腸癌和胃癌的四項臨床研究進展迅速

1 個附件

2015 年3 月6 日，週五：和黃醫藥今日宣布呋喹替尼（HMPL-013）以非小細胞肺癌為適應症的中國II 期臨床試驗完成受試者入組。呋喹替尼是和黃醫藥獨立研發的血管細胞內皮生長因子受體（V

查看公告 (PDF)

公告及新聞稿, 集團 | 2015-02-26

Final Results for the year ended 31 December 2014

For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and

公告及新聞稿, 其他業務, 新聞稿 | 2015-01-29

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China

Press Release - London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),

公告及新聞稿, 監管通知 | 2015-01-26

Notice of Announcement of 2014 Final Results

London: Monday, 26 January 2015: Chi-Med will be announcing its final results for the year ended 31 December 2014 on Thursday, 26 February 2015. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall

公告及新聞稿, 監管通知 | 2014-12-31

Total Voting Rights

公告及新聞稿, 監管通知 | 2014-12-29

Blocklisting Six Monthly Return

演示文稿, 科學出版物 | 2014-12-23

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)

公告及新聞稿, 腫瘤學 / 免疫學 | 2014-12-15

呋喹替尼治療結直腸癌的III期臨床試驗（FRESCO）啟動

1 個附件

2014年12月15日: 和黃醫藥今日宣布呋喹替尼（HMPL-013）以結直腸癌為適應症的中國III期臨床試驗（FRESCO）正式啟動。呋喹替尼是一種新型高選擇性抑制血管細胞內皮生長因子受體（VEGFR）的小�

查看公告 (PDF)

公告及新聞稿, 監管通知 | 2014-11-20

Director's Shareholding

公告及新聞稿, 監管通知 | 2014-10-31

Total Voting Rights

演示文稿, 科學出版物 | 2014-10-14

ACR/ARHP 2014: HM-0523 (HMPL-523), a novel Syk inhibitor, blocks glomerulonephritis and extends life spans in lupus prone MRL/lpr mice

1 個附件

View Poster (JPG)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2014-10-07

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014

Press Release - London: Tuesday, 7 October 2014: Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London o

公告及新聞稿, 其他業務, 新聞稿 | 2014-10-01

Chi-Med and Merck Serono sign co-promotion agreement

Press Release - London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company L

1 2 3 4 5 6 7 8 9 10 11 12 13 14

16 17 18 19 20